WO2005010049A3 - Tgf-beta1 ligands - Google Patents
Tgf-beta1 ligands Download PDFInfo
- Publication number
- WO2005010049A3 WO2005010049A3 PCT/US2004/018921 US2004018921W WO2005010049A3 WO 2005010049 A3 WO2005010049 A3 WO 2005010049A3 US 2004018921 W US2004018921 W US 2004018921W WO 2005010049 A3 WO2005010049 A3 WO 2005010049A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- beta1
- tgf
- ligands
- reagents
- isolated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04776554A EP1646655A2 (en) | 2003-07-09 | 2004-07-06 | Tgf-beta1 ligands |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48582003P | 2003-07-09 | 2003-07-09 | |
US60/485,820 | 2003-07-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005010049A2 WO2005010049A2 (en) | 2005-02-03 |
WO2005010049A3 true WO2005010049A3 (en) | 2005-08-18 |
Family
ID=34102666
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/018921 WO2005010049A2 (en) | 2003-07-09 | 2004-07-06 | Tgf-beta1 ligands |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP1646655A2 (en) |
WO (1) | WO2005010049A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9371374B2 (en) | 2013-03-14 | 2016-06-21 | Abbott Laboratories | HCV core lipid binding domain monoclonal antibodies |
US9399676B2 (en) | 2013-05-06 | 2016-07-26 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7467177B2 (en) | 2003-12-29 | 2008-12-16 | Xilinx, Inc. | Mathematical circuit with dynamic rounding |
HUE042689T2 (en) | 2005-02-08 | 2019-07-29 | Genzyme Corp | Antibodies to tgfbeta |
ATE505489T1 (en) | 2005-04-22 | 2011-04-15 | Lilly Co Eli | TGF-BETA-1 SPECIFIC ANTIBODIES |
CA2632799A1 (en) * | 2005-12-23 | 2007-07-05 | Eli Lilly And Company | Tgf-beta binding compositions |
ES2673822T3 (en) * | 2006-07-18 | 2018-06-25 | Sanofi | Antagonist antibody against EphA2 for cancer treatment |
PL2083863T3 (en) | 2006-10-03 | 2015-08-31 | Genzyme Corp | Antibodies to tgf-beta for use in the treatment of infants at risk of developing bronchopulmonary dysplasia |
US8642031B2 (en) | 2006-11-02 | 2014-02-04 | Acceleron Pharma, Inc. | Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof |
US10059756B2 (en) | 2006-11-02 | 2018-08-28 | Acceleron Pharma Inc. | Compositions comprising ALK1-ECD protein |
RU2559532C2 (en) | 2006-11-02 | 2015-08-10 | Акселерон Фарма, Инк. | Antagonists of alk1 receptor and ligands and their application |
CA2723449C (en) | 2008-05-02 | 2020-01-21 | Acceleron Pharma Inc. | Methods and compositions based on alk1 antagonists for modulating angiogenesis and pericyte coverage |
KR20110044992A (en) * | 2008-07-02 | 2011-05-03 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | TVF-β antagonist multi-target binding protein |
EP2497782A1 (en) * | 2011-03-08 | 2012-09-12 | Alzinova AB | Anti oligomer antibodies and uses thereof |
EP2737083A1 (en) | 2011-07-27 | 2014-06-04 | INSERM (Institut National de la Santé et de la Recherche Scientifique) | Methods for diagnosing and treating myhre syndrome |
CA2853484C (en) | 2011-10-26 | 2018-08-21 | Seattle Children's Research Institute | Cysteamine in the treatment of fibrotic disease |
CN110947002A (en) * | 2012-05-01 | 2020-04-03 | 约翰霍普金斯大学 | Compositions and methods for treating or preventing osteoarthritis |
US20150284452A1 (en) * | 2012-11-13 | 2015-10-08 | Iogenetics, Llc | Antimicrobial compositions |
CN105228649B (en) | 2013-03-14 | 2019-01-18 | 雅培制药有限公司 | HCV Ag-Ab combination measurement is with method and used in composition therein |
MX2015012824A (en) | 2013-03-14 | 2016-06-24 | Abbott Lab | Hcv ns3 recombinant antigens and mutants thereof for improved antibody detection. |
EP3685848B1 (en) | 2013-11-21 | 2021-09-15 | The Brigham and Women's Hospital, Inc. | Compositions and methods for treating pulmonary hypertension |
JP2018536628A (en) | 2015-10-07 | 2018-12-13 | オービーアイ ファーマ インコーポレイテッド | Novel carbohydrate antibody, pharmaceutical composition and use thereof |
TWI832600B (en) | 2017-01-20 | 2024-02-11 | 美商健臻公司 | Bone-targeting antibodies |
TW202313678A (en) | 2017-01-20 | 2023-04-01 | 法商賽諾菲公司 | Anti-tgf-beta antibodies and their use |
EP3707510B1 (en) | 2017-11-06 | 2024-06-26 | F. Hoffmann-La Roche AG | Diagnostic and therapeutic methods for cancer |
US20220177978A1 (en) | 2019-04-02 | 2022-06-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
WO2023080900A1 (en) | 2021-11-05 | 2023-05-11 | Genentech, Inc. | Methods and compositions for classifying and treating kidney cancer |
WO2024077095A1 (en) | 2022-10-05 | 2024-04-11 | Genentech, Inc. | Methods and compositions for classifying and treating bladder cancer |
WO2024077166A1 (en) | 2022-10-05 | 2024-04-11 | Genentech, Inc. | Methods and compositions for classifying and treating lung cancer |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997013844A1 (en) * | 1995-10-06 | 1997-04-17 | Cambridge Antibody Technology Limited | Specific binding members for human transforming growth factor beta; materials and methods |
WO2000066631A1 (en) * | 1999-04-30 | 2000-11-09 | Cambridge Antibody Technology Limited | SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS FOR TGFβ¿1? |
-
2004
- 2004-07-06 WO PCT/US2004/018921 patent/WO2005010049A2/en not_active Application Discontinuation
- 2004-07-06 EP EP04776554A patent/EP1646655A2/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997013844A1 (en) * | 1995-10-06 | 1997-04-17 | Cambridge Antibody Technology Limited | Specific binding members for human transforming growth factor beta; materials and methods |
WO2000066631A1 (en) * | 1999-04-30 | 2000-11-09 | Cambridge Antibody Technology Limited | SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS FOR TGFβ¿1? |
Non-Patent Citations (5)
Title |
---|
ELLINGSWORTH L R ET AL: "TRANSFORMING GROWTH FACTOR-BETAS ARE EQUIPOTENT GROWTH INHIBITORS OF INTERLEUKIN-1-INDUCED THYMOCYTE PROLIFERATION", CELLULAR IMMUNOLOGY, vol. 114, no. 1, 1988, pages 41 - 54, XP009042444, ISSN: 0008-8749 * |
FLANDERS K C ET AL: "ANTIBODIES TO PEPTIDE DETERMINANTS IN TRANSFORMING GROWTH FACTOR BETA AND THEIR APPLICATIONS", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 27, 1988, pages 739 - 746, XP002044723, ISSN: 0006-2960 * |
LUCAS C ET AL: "THE AUTOCRINE PRODUCTION OF TRANSFORMING GROWTH FACTOR-BETA1 DURING LUMPHOCYTE ACTIVATION A STUDY WITH A MONOCLONAL ANTIBODY-BASED ELISA", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 145, 1 September 1990 (1990-09-01), pages 1415 - 1422, XP000917385, ISSN: 0022-1767 * |
Monoclonal anti-TGF-b1 antibody. R&D Systems, Ordering Information, Catalog Number: MAB2401, 29.1.2003. * |
SHAH M ET AL: "NEUTRALISATION OF TGF-BETA1 AND TGF-BETA2 OR EXOGENOUS ADDITION OF TGF-BETA3 TO CUTANEOUS RAT WOUNDS REDUCES SCARRING", JOURNAL OF CELL SCIENCE, CAMBRIDGE UNIVERSITY PRESS, LONDON, GB, vol. 108, no. PART 3, 1 March 1995 (1995-03-01), pages 985 - 1002, XP000609005, ISSN: 0021-9533 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9371374B2 (en) | 2013-03-14 | 2016-06-21 | Abbott Laboratories | HCV core lipid binding domain monoclonal antibodies |
US9399676B2 (en) | 2013-05-06 | 2016-07-26 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
US9573995B2 (en) | 2013-05-06 | 2017-02-21 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
Also Published As
Publication number | Publication date |
---|---|
EP1646655A2 (en) | 2006-04-19 |
WO2005010049A2 (en) | 2005-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005010049A3 (en) | Tgf-beta1 ligands | |
WO2006017538A3 (en) | Hk1-binding proteins | |
WO2004037988A3 (en) | Methods for synthesizing complementary dna | |
WO2005107491A3 (en) | Multi-lectin affinity chromatography and uses thereof | |
WO2006039470A9 (en) | Anti- amyloid antibodies, compositions, methods and uses | |
WO2007133290A3 (en) | Anti-ox40l antibodies and methods using same | |
EP1623011A4 (en) | IL-23p40 SPECIFIC IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES | |
DK1874818T3 (en) | TGF-Beta 1-specific antibodies | |
WO2006020947A3 (en) | Phosphonate fluorescent dyes and conjugates | |
WO2006058237A3 (en) | Polymer-coated substrates for binding biomolecules and methods of making and using thereof | |
WO2007081720A3 (en) | Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer | |
WO2004029219A3 (en) | Cell-based rna interference and related methods and compositions | |
WO2003050243A3 (en) | Novel genes encoding colon cancer antigens | |
WO2006028429A3 (en) | Peptides for targeting the prostate specific membrane antigen | |
EP1836214A4 (en) | Compositions, methods, and kits for enhancing protein expression, solubility and isolation | |
WO2005087793A3 (en) | Immunostimulatory compositions and uses thereof | |
WO2004013160A3 (en) | Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof | |
WO2005123913A3 (en) | Reversibly modified thermostable enzyme compositions and methods of making and using the same | |
WO2006054297A3 (en) | Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis | |
AU2002359495A1 (en) | Anti-tnf antibodies, compositions, methods and uses | |
WO2006073971A3 (en) | Binding protein with a scaffold for varying specificity | |
WO2006063028A3 (en) | Immunostimulatory compositions and uses thereof | |
WO2005062947A3 (en) | Methods and compositions for identifying rna-binding proteins | |
AU2003225976A1 (en) | Anti-tnf antibodies, compositions, methods and uses | |
WO2004110365A3 (en) | Liver related disease compositions and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004776554 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004776554 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2004776554 Country of ref document: EP |